Clinical relevance of immunoactive mistletoe lectin-I.
Journal/Book: ANTI-CANCER-DRUGS, 1997, Vol/Iss/Pg. 8/SUPPL. 1 (S53-S55), ISSN:0959-4973, Full Title: Anti-Cancer Drugs..
Abstract: Recent investigations have shown that defined, non-toxic doses of thegalactoside-specific mistletoe lectin (mistletoe lectin-I, a constituentof clinically approved plant extracts) have immunomodulatory potencies.The obvious ability of certain lectins (e.g. mistletoe lectin-I) toactivate (non-)specific defence mechanisms supports the assumption thatlectin-carbohydrate interactions may induce clinically beneficialimmunomodulation. Initial clinical trials were promising and currentlyprospectively randomized multicentre trials are being performed toevaluate the ability of complementary mistletoe lectin-l treatment toreduce the rate of tumour recurrences and metastases, to improve theoverall survival as well as the quality of life and to exertimmunoprotection in cancer patients under tumour destructive therapy.COPYRIGHT BY Elsevier Science BV, Amsterdam, Netherlands END OF DOCUMENT